Granular segment
Pharma / generics
Pharma and generics exposure is more about manufacturing scale, product portfolios, pricing, legal risk, and balance sheets than early-stage science.
Current reported exposure$183M
Tagged bought / added$0
Tagged sold / reduced$217M
Tracked funds1
Segment overview
This segment groups health-care businesses by the economic engine behind the exposure: discovery tools, drug development, scaled pharma manufacturing, or patient-service delivery. The risk profile changes sharply across those layers.
For 13F readers, the tag helps separate long-duration clinical optionality from cash-flowing service or product businesses. It also makes it easier to see when a fund is taking scientific risk versus reimbursement, utilization, or platform-consolidation risk.
What it covers
- Generic drug manufacturing
- Specialty pharma portfolios
- Biosimilars
- Distribution and supply reliability
What to watch
- Pricing pressure
- Patent cliffs and launches
- Manufacturing quality issues
- Leverage and litigation risk
Tracked fund exposure
Duquesne Family Office LLC
Stanley Druckenmiller · Q4 2025 filed 2026-02-17
4.1% of reported 13F $183M
Large specialty-pharma and generic-drug manufacturers.
Largest tracked holdings
| Ticker | Name | Value | Instrument |
|---|---|---|---|
| TEVA | TEVA PHARMACEUTICAL-SP ADR | $183M | SH |
Quarter activity
| Ticker | Action | Value |
|---|---|---|
| TEVA | Trimmed | -$217M |